Related Experiment Video
Updated: Feb 8, 2026
Orthotopic Mouse Model of Colorectal Cancer
Published on: December 4, 2007
Research progress on common adverse events caused by targeted therapy for colorectal cancer
Bo Zhang1, Chenyan Fang2, Dehou Deng1
1Department of Integrated Chinese and Western Medicine, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China.
Abstract:
As targeted drug therapy is increasingly applied in the treatment of colon cancer, understanding and managing the adverse reactions of patients is becoming increasingly important. The present review examines the mechanisms of and adverse reactions to the most commonly used targeted drugs for colon cancer, and discusses methods of coping with these adverse reactions. Approved targeted drugs for metastatic colon cancer include monoclonal antibodies targeting vascular endothelial growth factor (VEGF), including bevacizumab, ziv-aflibercept and regorafenib, and monoclonal antibodies targeting epithelial growth factor receptor (EGFR), including cetuximab and panitumumab. The present review assesses the major adverse effects of these drugs and methods of dealing with reactions to them. VEGF inhibitors primarily result in cardiovascular and kidney problems. Meanwhile, EGFR receptor inhibitors are frequently reported to cause rashes, diarrhea and hypertension, and are reviewed from the point of view of resulting electrolyte disturbances.
Insights
Targeted therapies for colon cancer, including VEGF and EGFR inhibitors, are effective but cause side effects. This review details adverse reactions and management strategies for these important colon cancer treatments.
Area of Science:
- Oncology
- Pharmacology
Background:
- Targeted drug therapy is a growing treatment modality for colon cancer.
- Understanding and managing adverse drug reactions (ADRs) is crucial for patient care.
Purpose of the Study:
- To review the mechanisms and adverse reactions of commonly used targeted drugs for colon cancer.
- To discuss strategies for managing these adverse reactions.
Main Methods:
- Literature review of approved targeted drugs for metastatic colon cancer.
- Analysis of adverse effects associated with vascular endothelial growth factor (VEGF) and epithelial growth factor receptor (EGFR) inhibitors.
- Examination of management strategies for identified adverse reactions.
Main Results:
- VEGF inhibitors (bevacizumab, ziv-aflibercept, regorafenib) are associated with cardiovascular and kidney issues.
- EGFR inhibitors (cetuximab, panitumumab) can cause rashes, diarrhea, hypertension, and electrolyte disturbances.
- The review details specific adverse effects and coping mechanisms for each drug class.
Conclusions:
- Effective management of ADRs is essential for optimizing targeted therapy in colon cancer patients.
- Awareness of specific side effect profiles for VEGF and EGFR inhibitors aids in proactive patient care.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:24Common Ion Effect
01:12Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...